ZURICH (Reuters) - A combination of Roche's Tecentriq immunotherapy with chemotherapy helped people with a form of lung cancer live significantly longer than patients on chemotherapy alone, a late-stage trial cited by the Swiss drugmaker showed.
Original Article: Roche's Tecentriq meets targets in lung cancer trial